test results, page-6

The Announcement concerns Laboratory studies:

http://www.marshalledwardsinc.com/index04.cfm?section=04&status=1&id=136

However it was noted in a much earlier clinical trial that there was regression and stabilisation of some tumours. That was a long time ago and by now they would be doing updated prescriptions, I would say.

Re NV07a, agree Munch that the valuation could be close to $6.25 per share on Announcement of a Commercialisation contract.

However, I have allocated a market share price of $3.30 per share for this drug alone.

Current share price price is only $3.15.

I have indicated previously that I have positive feelings for that Skin Cancer trial. The reasons can be found in earlier posts.

Cheers,

Gerry Stolwyk